LU90312I2 - S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène - Google Patents

S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène

Info

Publication number
LU90312I2
LU90312I2 LU90312C LU90312C LU90312I2 LU 90312 I2 LU90312 I2 LU 90312I2 LU 90312 C LU90312 C LU 90312C LU 90312 C LU90312 C LU 90312C LU 90312 I2 LU90312 I2 LU 90312I2
Authority
LU
Luxembourg
Prior art keywords
ethyl
phenylcarbamate
dimethyl
amino
methyl
Prior art date
Application number
LU90312C
Other languages
English (en)
French (fr)
Original Assignee
Proterra Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proterra Ag filed Critical Proterra Ag
Publication of LU90312I2 publication Critical patent/LU90312I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
LU90312C 1985-03-05 1998-11-04 S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène LU90312I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (1)

Publication Number Publication Date
LU90312I2 true LU90312I2 (fr) 1999-01-06

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90312C LU90312I2 (fr) 1985-03-05 1998-11-04 S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène

Country Status (25)

Country Link
US (1) US4948807A (forum.php)
EP (1) EP0193926B3 (forum.php)
JP (1) JPS61225158A (forum.php)
KR (1) KR940010764B1 (forum.php)
AT (1) ATE58130T1 (forum.php)
AU (1) AU595504B2 (forum.php)
CA (1) CA1284501C (forum.php)
CY (2) CY1748A (forum.php)
DE (2) DE3675408D1 (forum.php)
DK (1) DK172851B1 (forum.php)
ES (1) ES8801193A1 (forum.php)
FI (1) FI87197C (forum.php)
GR (1) GR860586B (forum.php)
HK (1) HK130293A (forum.php)
HU (1) HU201297B (forum.php)
IE (1) IE58838B1 (forum.php)
IL (1) IL74497A (forum.php)
LU (1) LU90312I2 (forum.php)
MY (1) MY137602A (forum.php)
NL (1) NL980031I2 (forum.php)
NZ (1) NZ215348A (forum.php)
PH (1) PH23325A (forum.php)
PL (1) PL146301B1 (forum.php)
PT (1) PT82127B (forum.php)
ZA (1) ZA861653B (forum.php)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
PT951284E (pt) * 1996-12-18 2003-12-31 Yissum Res Dev Co Derivados de feniletilamina
JP4222632B2 (ja) 1996-12-18 2009-02-12 テバ・ファーマシューティカル・インダストリーズ・リミテッド アミノインダン誘導体
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DE69802498T2 (de) * 1997-01-17 2002-07-04 Takeda Chemical Industries, Ltd. Idebenon enthaltendes kombinationspräparat zur alzheimer behandlung
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
EP2960325B1 (en) 2000-01-28 2017-09-27 DSM IP Assets B.V. Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
WO2003101917A2 (en) * 2002-05-31 2003-12-11 Sun Pharmaceutical Industries Limited A process for the preparation of phenylcarbamates
KR100935615B1 (ko) 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20070085033A (ko) * 2003-10-21 2007-08-27 코루시드 파마슈티컬즈 인코포레이티드 콜린에스테라제를 억제하고 약리 활성제를 방출하는카르바모일 에스테르
BRPI0416989A (pt) 2003-11-26 2007-02-06 Pfizer Prod Inc derivados aminopirazole como inibidores gsk-3
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2005072713A2 (en) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
EP1718291A1 (en) * 2004-02-19 2006-11-08 Novartis AG Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
RU2393148C2 (ru) * 2004-11-08 2010-06-27 Эмкюр Фармасьютикалз Лимитед Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
CN103142570A (zh) * 2005-12-09 2013-06-12 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil 用于神经保护的用途
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
CA2677241A1 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
DK2582799T3 (en) 2010-06-17 2018-02-12 Codexis Inc BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6334511B2 (ja) 2012-04-14 2018-05-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規方法
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
EP0193926A2 (en) 1986-09-10
EP0193926B3 (en) 2010-04-28
ES8801193A1 (es) 1988-01-01
JPH0255416B2 (forum.php) 1990-11-27
IL74497A0 (en) 1985-06-30
NL980031I1 (nl) 1999-01-04
AU5428486A (en) 1986-09-11
CY1748A (en) 1994-06-03
DK99186A (da) 1986-09-06
DK99186D0 (da) 1986-03-04
FI87197C (fi) 1992-12-10
MY137602A (en) 2009-02-27
EP0193926A3 (en) 1987-05-13
AU595504B2 (en) 1990-04-05
JPS61225158A (ja) 1986-10-06
CY2004004I1 (el) 2009-11-04
GR860586B (en) 1986-07-07
HK130293A (en) 1993-12-03
DE3675408D1 (de) 1990-12-13
PL146301B1 (en) 1989-01-31
NL980031I2 (nl) 1999-03-01
KR860007207A (ko) 1986-10-08
KR940010764B1 (ko) 1994-11-11
CY2004004I2 (el) 2009-11-04
HU201297B (en) 1990-10-28
CA1284501C (en) 1991-05-28
IL74497A (en) 1990-02-09
ATE58130T1 (de) 1990-11-15
FI860914A0 (fi) 1986-03-04
FI860914L (fi) 1986-09-06
HUT41718A (en) 1987-05-28
IE58838B1 (en) 1993-11-17
IE860558L (en) 1986-09-05
US4948807A (en) 1990-08-14
ZA861653B (en) 1987-10-28
PT82127B (pt) 1988-07-01
FI87197B (fi) 1992-08-31
ES552627A0 (es) 1988-01-01
PT82127A (en) 1986-04-01
PH23325A (en) 1989-07-14
EP0193926B1 (en) 1990-11-07
DE19875046I1 (de) 2003-09-04
NZ215348A (en) 1990-04-26
DK172851B1 (da) 1999-08-16

Similar Documents

Publication Publication Date Title
LU90312I2 (fr) S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène
EG18379A (en) Novel pharmacological compounds
MY105344A (en) New sulphonyl compounds
NO981393D0 (no) Guanidinoproteasehemmere
ES461077A1 (es) Procedimiento para la preparacion de 2-bencilpirrolidinas.
ES456243A1 (es) Un procedimiento de preparacion de compuestos de aminoalcoxi4-(2h)-piranona-2, sustituidos en posicion 3 y condensados en posicion 5,6.
IL76345A (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
PH24207A (en) 2-acylamino-6-amino-4,5,6,7-tetrahydrobenzothiazoles
MY102026A (en) Antiasthmatic.
ES8602021A1 (es) Procedimiento de preparar compuestos espirociclicos antihi- pertensivos
ES8205218A1 (es) Un procedimiento para la preparacion de pirrolilpiperidinas utiles como agentes antidepresivo.
ES8608887A1 (es) Procedimiento para la obtencion de preparados combinados antihipertensores y antianginicos a base de dihidropiridina y bloquear beta.
ZA828877B (en) Therapeutically useful 3,7a-diazacyclohepta(j,k)fluorene derivatives
AU476756B2 (en) PHARMACOLOGICALLY ACTIVE 4, 8-DIMETHOXY-FURO-(3&#39;,2&#39;-F) BENZOXAZOL-2-yl ACETHYDROXAMIC ACID
AU6816787A (en) (Gem-heterocyclodimethanamine-N,N&#39;) platinum complexes
SU1297428A1 (ru) 54, 56:58, 60-дииндий (iii) дихлор-6, 11:19, 24:32, 37:45, 50-тетраимино-5-, 52:13, 18:20, 31:39, 44-тетранитрилоктабензо [с, д, е, р, и, у, d, h] (1, 10, 19, 28) - тетраазациклогексатриаконтин как полупроводник
IT8422675A0 (it) Un inoculo per la fermentazione procedimento per la produzione di anaerobica di coenzina b 12.
UA11675A1 (uk) 1-БЕtА-ОКСИЕТИЛАМІHО-3-КЕТО-5,5-ДИМЕТИЛЦИКЛОГЕКСЕH -1, ЯКИЙ МАЄ АHАЛЬГЕТИЧHУ АКТИВHІСТЬ
SU1269465A1 (ru) Способ получения 2-анилино-7-гидрокси-6н-1,3,4-тиадиазепинов
JPS5283520A (en) Novel 2-arylthio-cyclopentanones
IT8501203A0 (it) Apparecchiatura per la diffusione audio-video-stampa di messaggi di utilita&#39;pubblica.
SU1045566A1 (ru) Хлорангидрид 3,4-дициано - 4′- -карбоксидифенилоксида в качестве полупродукта для синтеза тетранитрилов ароматических тетракарбоновых кислот, тетранитрилы ароматических тетракарбоновых кислот как мономеры для синтеза полигексазоцикланов и полигексазоцикланы как материалы для электропроводящих покрытий
SU1297421A1 (ru) ГИДРОХЛОРИДЫ 3-ЗАМЕЩЕННЫХ 2-ЭТИЛ-4-МЕТИЛПИРАЗОЛО(1,5-а)-БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ АНТИАРИТМИЧЕСКОЙ АКТИВНОСТЬЮ